PD-1 in complex with pembrolizumab Fab
Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.
Pembrolizumab was approved for medical use in the United States in 2014. In 2017, the US Food and Drug Administration (FDA) approved it for any unresectable or metastatic solid tumor with certain genetic anomalies (mismatch repair deficiency or microsatellite instability).
You can now get a table of the values of the potential energy of electrostatic interaction between PD-1 and FAB1 just for 156 EURO
You can now get a table of the values of the potential energy of electrostatic interaction between PD-1 and FAB2 just for 156 EURO
You can order alanine scanning or mutagenesis (from 15 substitutions of amino acid residues) from 3500 Euro. A detailed study of the properties of the protein complex Fab1-Fab2-PD1 from 7890 Euro